


AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1. (currently amended) A compound having formula (I) below:



(I)

in which:


- R₁ represents:

- (i) a -CH₃ radical,
- (ii) a radical -CH₂-O-R₅,
- (iii) a radical -COR₆,

R₅ and R₆ having the meanings given below,

- Ar represents a radical selected from the group of radicals of formulae (a) - (e)

below:



R_7 having the meaning given below

- R_2 and R_3 , which may be identical or different, independently represent a radical selected from the group consisting of:

(i) a hydrogen atom,

(ii) a radical selected from tert-butyl, 1-methylcyclohexyl and 1-adamantyl radicals,

(iii) a radical $-OR_8$, R_8 having the meaning given below, and

(iv) a polyether radical, it being understood that at least one of the radicals R_2 or R_3 represents a radical (ii),

- R_2 and R_3 taken together can form, with the adjacent aromatic ring, a 5- or 6-membered saturated ring optionally substituted with methyl groups and/or optionally interrupted with an oxygen or sulphur atom,

- R_4 represents a hydrogen atom, a halogen atom, a lower alkyl radical, a radical OR_9 , a polyether radical or a radical COR_{10} ,

R_9 and R_{10} having the meanings given below,

- R_5 represents a hydrogen atom, a lower alkyl radical or a radical COR_{11} ,

R_{11} having the meaning given below,

- R_6 represents a radical selected from the group consisting of:


(i) a hydrogen atom,

(ii) a lower alkyl radical,

(iii) a radical OR_{12} ,


R_{12} having the meaning given below, and

(iv) a radical of formula



R' and R'' having the meanings given below,

- R_7 represents a hydrogen atom, a halogen atom, a lower alkyl radical, a nitro radical, a radical OR_{13} , a polyether radical or a radical of the following formula:



R_{13} , R_{14} and R_{15} having the meanings given below,

- R_8 represents a hydrogen atom, a lower alkyl radical, an optionally substituted aryl radical, an optionally substituted aralkyl radical, a monhydroxyalkyl or polyhydroxyalkyl radical or a lower acyl radical,

- R_9 represents a hydrogen atom, a lower alkyl radical, an optionally substituted aryl radical, an optionally substituted aralkyl radical, a monohydroxyalkyl or polyhydroxyalkyl radical, a lower acyl radical, a radical $-(CH_2)_n-COOR_{16}$ or a radical $-(CH_2)_n-X$,
 n , R_{16} and X having the meanings given below,
- R_{10} and R_{11} , which may be identical or different, represent a lower alkyl radical,
- R_{12} represents a hydrogen atom, a lower alkyl radical, an optionally substituted aryl or aralkyl radical, a monohydroxyalkyl radical or a polyhydroxyalkyl radical,
- R' and R'' , which may be identical or different, represent a hydrogen atom, a lower alkyl radical, or an optionally substituted aryl radical or an amino acid residue, ~~or alternatively R' and R'' taken together can form, with the nitrogen atom, a heterocycle,~~
- R_{13} represents a hydrogen atom or a lower alkyl radical,
- R_{14} and R_{15} , which may be identical or different, represent a hydrogen atom or a lower alkyl radical,
- R_{16} represents a hydrogen atom or a lower alkyl radical,
- n represents an integer between 1 and 12 inclusive,
- X represents a halogen atom, and the optical and geometrical isomers of the said compounds of formula (I), as well as the salts thereof.

2. (previously presented) A compound according to Claim 1, which are in the form of salts of an alkali metal or alkaline-earth metal, of zinc, of an organic amine or of an inorganic or organic acid.

3. (previously presented) A compound according to claim 1, wherein the lower alkyl radicals are selected from the group consisting of methyl, ethyl, isopropyl, butyl and tert-butyl radicals.

4. (previously presented) A compound according to claim 1, wherein the monohydroxyalkyl radicals correspond to radicals containing 2 or 3 carbon atoms, it being possible for the monohydroxyalkyl radical to be protected in the form of acetyl or tertbutyldimethylsilyl.

5. (previously presented) A compound according to claim 1, wherein the polyhydroxyalkyl radicals are selected from the group consisting of 2,3-dihydroxypropyl, 2,3,4-trihydroxybutyl and 2,3,4,5-tetrahydroxypentyl radicals or a pentaerythritol residue, it being possible for the hydroxyl groups to be protected in the form of acetyls or tert-butyl dimethylsilyls.

6. (currently amended) A compound according to claim 1, wherein the aryl radicals correspond to a phenyl radical, optionally substituted with at least one halogen[[,]] or one hydroxyl ~~or one nitro~~ function.

7. (currently amended) A compound according to claim 1, wherein the aralkyl radicals are selected from the group consisting of benzyl and phenethyl radicals optionally substituted with at least one halogen[[,]] or one hydroxyl ~~or one nitro~~ function.

8. (previously presented) A compound according to claim 1, wherein the lower acyl radicals are selected from the group consisting of an acetyl radical and a propionyl radical.

9. (previously presented) A compound according to claim 1, wherein the polyether radicals are selected from the group consisting of methoxymethyl ether, methoxyethoxymethyl ether and methylthiomethyl ether radicals.

10. (previously presented) A compound according to claim 1, wherein the amino acid residues are selected from the group consisting of residues derived from lysine, glycine and aspartic acid.

11. (previously presented) A compound according to claim 1, wherein the heterocyclic radicals are selected from the group consisting of piperidino, morpholino, pyrrolidino and piperazino radicals, optionally substituted in position 4 with a C₁-C₆ alkyl radical or with a mono- or polyhydroxyalkyl radical.

12. (previously presented) A compound according to Claim 1, which are taken, alone or as mixtures, from the group consisting of:

ethyl 4-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthylselanyl)benzoate, 4-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthylselanyl)benzoic acid, ethyl 6-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthylselanyl)nicotinate, 6-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthylselanyl)nicotinic acid, ethyl 6-(5,5,8,8-tetramethyl-3-propoxy-5,6,7,8-tetrahydro-2-naphthylselanyl)nicotinate, 6-(5,5,8,8-tetramethyl-3-propoxy-5,6,7,8-tetrahydro-2-naphthylselanyl)nicotinic acid, 3-(4-tert-butylphenylselanyl)benzoic acid, 6-(4-tert-butylphenylselanyl)nicotinic acid, 4-(4-tert-butylphenylselanyl)benzoic acid, 4-(4,4-dimethylthiochroman-8-ylselanyl)benzoic acid, 3-(4,4-dimethylthiochroman-8-ylselanyl)benzoic acid, 6-(4,4-dimethylthiochroman-8-ylselanyl)nicotinic acid, 4-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthylselanyl)benzoic acid, 3-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthylselanyl)benzoic acid, 6-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthylselanyl)nicotinic acid, 4-[5-adamantan-1-yl-4-(2-methoxyethoxymethoxy)-2-methylphenylselanyl]benzoic acid, 3-[5-adamantan-1-yl-4-(2-methoxyethoxymethoxy)-2-

methylphenylselanyl]benzoic acid, 6-(4-methoxyethoxymethoxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthylselanyl)nicotinic acid, 3-(4-methoxyethoxymethoxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthylselanyl)benzoic acid, 4-(4-methoxyethoxymethoxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthylselanyl)-3-methoxybenzoic acid, 3-(4-methoxyethoxymethoxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthylselanyl)-4-methoxybenzoic acid, 6-(4-methoxymethoxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthylselanyl)nicotinic acid, 6-(3-methoxyethoxymethoxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthylselanyl)nicotinic acid, 2-(3-methoxyethoxymethoxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthylselanyl)nicotinic acid, 4-(3-methoxyethoxymethoxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthylselanyl)benzoic acid, 3-(3-methoxyethoxymethoxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthylselanyl)benzoic acid, 6-(3,5-di-tert-butyl-2-methoxymethoxyphenylselanyl)-nicotinic acid, 2-(3,5-di-tert-butyl-2-methoxymethoxyphenylselanyl)nicotinic acid, 4-(3,5-di-tert-butyl-2-methoxymethoxyphenylselanyl)benzoic acid, 3-(3,5-di-tert-butyl-2-methoxymethoxyphenylselanyl)-benzoic acid, 6-[4-adamantan-1-yl-3-benzyloxyphenylselanyl)nicotinic acid, 6-(3,5-di-tert-butyl-2-benzyloxyphenylselanyl)nicotinic acid, 3-methoxy-4-(4-benzyloxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthylselanyl)benzoic acid, 4-(4-benzyloxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthylselanyl)benzoic acid, 6-(4-benzyloxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthylselanyl)nicotinic acid, 3-methoxy-4-(3-benzyloxy-5,6,7,8-

tetrahydro-5,5,8,8-tetramethyl-2-naphthylselanyl)benzoic acid, 6-(3-benzyloxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthylselanyl)nicotinic acid, 4-(3-hexyloxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthylselanyl)-3-methoxybenzoic acid, 6-(3-hexyloxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthylselanyl)nicotinic acid, 4-(5-adamantan-1-yl-4-benzyloxy-2-methylphenylselanyl)-benzoic acid, 6-[3-(5-hydroxypentyloxy)-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthylselanyl]nicotinic acid, ethyl 4-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthylselanyl)benzoate, ethyl 4-(3-methoxyethoxymethoxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthylselanyl)benzoate, ethyl 4-(3-hydroxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthylselanyl)benzoate, 4-(3-hydroxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthylselanyl)benzoic acid, ethyl 6-(3-methoxyethoxymethoxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthylselanyl)nicotinate, ethyl 6-(3-hydroxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthylselanyl)nicotinate, 6-(3-hydroxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthylselanyl)nicotinic acid, ethyl 6-[3-(3-ethoxycarbonylpropoxy)-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthylselanyl]nicotinate, 6-[3-(3-carboxypropoxy)-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthylselanyl]nicotinic acid, ethyl 4-[3-(3-ethoxycarbonylpropoxy)-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthylselanyl]benzoate, 4-[3-(3-carboxypropoxy)-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthylselanyl]benzoic acid, ethyl 4-[3-(7-methoxycarbonylheptyloxy)-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthylselanyl]benzoate, 4-[3-(7-carboxyheptyloxy)-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthylselanyl]benzoic acid, ethyl 6-[3-(7-

methoxycarbonylheptyloxy)-5,5,8,8-tetra-methyl-5,6,7,8-tetrahydro-2-naphthylselanyl nicotinate, 6-[3-(7-carboxyheptyloxy)-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthylselanyl nicotinic acid, ethyl 6-[3-(2-acetoxyethoxy)-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthylselanyl] nicotinate, 6-[3-(2-hydroxyethoxy)-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthylselanyl] nicotinic acid, ethyl 4-[3-(2-acetoxyethoxy)-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthylselanyl] benzoate, 4-[3-(2-hydroxyethoxy)-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthylselanyl] benzoic acid, 6-(3-adamantan-1-yl-4-methoxyphenylselanyl) nicotinic acid, [6-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthylselanyl)-3-pyridyl] methanol, N-ethyl-6-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthylselanyl) nicotinamide, morpholin-4-yl-[6-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthylselanyl)-3-pyridyl] methanone, N-(4-hydroxyphenyl)-6-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthylselanyl) nicotinamide, 6-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthylselanyl) pyridine-3-carbaldehyde.

13. (previously presented) A compound according to Claim 1, which have at least one, of the following characteristics:

- R_1 represents a radical COR_6
- Ar represents a radical of formula (a) or (b)

- R_2 or R_3 represents an adamantyl radical or R_2 and R_3 taken together form, with the adjacent aromatic ring, a 5- or 6-membered saturated ring optionally substituted with methyl groups and/or optionally interrupted with an oxygen or sulphur atom.

14. (canceled)

15. (previously presented) A method for treating dermatological complaints associated with a keratinization disorder which has a bearing on differentiation and on proliferation; for treating other types of keratinization disorder; for treating other dermatological complaints associated with a keratinization disorder with an inflammatory and/or immunoallergic component; for treating inflammatory complaints which have no keratinization disorder; for treating all dermal or epidermal proliferations, whether benign or malignant and whether they are of viral origin or otherwise; for treating other dermatological disorders such as bullosis and collagen diseases; for treating certain ophthalmological disorders; for repairing or combating ageing of the skin, whether this is lightinduced or chronological ageing, or for reducing actinic keratoses and pigmentations, or any pathologies associated with chronological or actinic ageing; for preventing or curing the stigmata of epidermal and/or dermal atrophy induced by local or systemic corticosteroids, or any other form of cutaneous atrophy; for preventing or treating cicatrization disorders or for preventing or repairing stretchmarks, or for promoting cicatrization; for combating disorders of sebaceous functioning hyperseborrhoea of acne or;

for treating or preventing cancerous or precancerous states; for the treatment of inflammatory complaints; for the treatment of any general or skin complaint of viral origin; for the prevention or treatment of alopecia; for the treatment of dermatological complaints having an immunological component; for the treatment of complaints of the cardiovascular system; for the treatment of skin disorders due to an exposure to U.V. radiation comprising administering to a subject an effective amount of the compound according to claim 1 to a subject.

16. (previously presented) Pharmaceutical composition comprising, in a pharmaceutically acceptable support, at least one of the compounds as defined in claim 1.

17. (previously presented) Composition according to Claim 16, wherein the concentration of compound(s) according to claim 1 is between 0.001 % and 5 % by weight relative to the composition as a whole.

18. (previously presented) Cosmetic composition] comprising, in a cosmetically acceptable support, at least one of the compounds as defined in claim 1.

19. (previously presented) Composition according to Claim 18, wherein the concentration of compounds is between 0.001 % and 3 % by weight relative to the composition as a whole.

20. (previously presented) A method for body or hair hygiene comprising administering an effective amount of the cosmetic composition according to claim 18 to a subject.